FDA

>

Latest News

Credit: Yurii Kibalnik | stock.adobe.com
Phase III SELECT-GCA Trial Results Lead to FDA Approval of Rinvoq for Giant Cell Arteritis

April 30th 2025

Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in adults, following robust data from the Phase III SELECT-GCA trial demonstrating its efficacy in achieving sustained remission and reducing glucocorticoid exposure.

Credit: ralwel | stock.adobe.com
Results of Phase III HERCULES, GEMINI 1 and 2 Trials Lead to FDA Priority Review for Tolebrutinib for Non-Relapsing Secondary Progressive MS

March 25th 2025

© WESTOCK - © WESTOCK - stock.adobe.com
Clinical Research, DEI Initiatives Caught in Political Headwinds Amidst Funding Freeze

February 13th 2025

Credit: alexlmx | stock.adobe.com
Analysis of Clinical Trial Characteristics Show Typical Drug Development Costs Are Lower Than Expected, Skewed by High-Cost Outliers

January 8th 2025

© photon_photo - © photon_photo - stock.adobe.com
Revolutionizing Oncology: Insights on the FDA’s Project Optimus and Dose Optimization

September 20th 2024

More News

© 2025 MJH Life Sciences

All rights reserved.